Num. Contratto:
IRSN LW 2024-0015

Coordinatore: NNGYK - NATIONAL CENTRE FOR PUBLIC HEALTH AND PHARMACY (Ungheria)

Responsabile ENEA: ANTONELLI FRANCESCA - SSPT-TECS-TEB (CASACCIA)

Ruolo ENEA: PARTNER

Sito Web: https://pianoforte-partnership.eu/imageomics/

Programma Quadro: HORIZON EUROPE

Programma UE: Euratom radioprotezione - Radioprotezione

Area Tematica: Radioprotection

Tipo Progetto: Programme Cofund Actions

Descrizione:

A major objective of PIANOFORTE is to innovate in ionising radiation based medical diagnostic and therapeutic applications combating cancer to improve patient health and safety. Combating cancer is in the focus of other EUinitiatives as well, such as the Samira action plan, Europe’s Beating Cancer Plan and Horizon Europe Mission on Cancer. IMAGEOMICS adheres to these initiatives by proposing new imaging modality to improve cancer diagnosis and solutions to increase the benefit of cancer patients from radiotherapy. The main aims of IMAGEOMICS are to improve benefit/risk ratio of breast cancer (BC) patients by identifying patients with a predicted favourable response to combined radiotherapy (RT) and immunotherapy and to develop new imaging modality with increased diagnostic potential and reduced ionizing radiation exposure. These aims will be realized through the following specific objectives: a) investigate how RT influences immunogenic heterogeneity of BC cells of different molecular subtypes using in vitro and in vivo approaches; b) test the applicability of nanoparticles for X ray fluorescence computed tomography (XFCT) to be used for the detection of BC heterogeneity; c) to identify local and systemic signatures that predict patient benefit from combined RT and immunotherapy and test their clinical applicability; d) to integrate data retrieved from experimental models and human studies with epidemiological data to build up a protocol for optimal patient stratification. High-throughput techniques such as immunopeptidome analysis and spatial multiomics analysis coupled with single cell imaging will be used. The innovative aspects of the project rely on providing an integrative analysis based on in vitro (3D bioprints, organ-on-a-chip systems), in vivo and human studies on markers reflecting interactions between BC RT and immunotherapy as well as investigating the applicability of molecularly targeted nanoparticles to be used in XFCT, opening the possibility for further developments in their theranostic application. The successful completion of IMAGEOMICS tasks is guaranteed by its multidisciplinary team, involving radiation physicists, radiation oncologists, radiation and molecular biologists, as well as epidemiologists, all strongly committed to advance radiation protection research for the benefit of the public and patients.

Attività svolta da ENEA:

L’ENEA rivestirà il ruolo di Partner. Non sono previste attività tecnico-scientifiche: il progetto prevede che l'ENEA dovrà garantire esclusivamente la gestione dei rapporti con la UE e il trasferimento del flusso economico verso l’Affiliated Entity (AE) “Laboratorio di Biofisica delle Radiazioni e Radiobiologia dell’Università di Pavia”

Note:

Posizione:
1774

Codice Atto:
PS5ABJ

Atto di approvazione ENEA:
47/2024/SSPT-TECS

Unità alla stipula:
SSPT-TECS-TEB

Costo eleggibile del Progetto: 1.405.230,00

Contributo al Progetto: 885.295,00

---

Costo eleggibile per ENEA: 20.000,00

Contributo ad ENEA: 12.600,00

Anno di stipula:
2024

Durata in mesi:
40

Data di inizio:
01-02-2024

Data di scadenza:
31-05-2027